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Clinical Inquiries provide answers to questions submitted by practicing family physicians to the 
Family Practice Inquiries Network (FPIN). Members of the network select questions based on 
their relevance to family medicine. Answers are drawn from an approved set of evidence-based 
resources and undergo peer review. The strength of recommendations and the level of evidence 
for individual studies are rated using criteria developed by the Evidence-Based Medicine 
Working Group (http://www.cebm.net/levels_of_evidence.asp). 
This series of Clinical Inquiries is coordinated for American Family Physician by John Epling, 
M.D., State University of New York Upstate Medical University, Syracuse, N.Y. The complete 
database of evidence-based questions and answers is copyrighted by FPIN. If you are interested 
in submitting questions to be answered or writing answers for this series, go to 
http://www.fpin.org or contact CI2Editor@fpin.org. 
Searchable Question 
Which patients with atrial fibrillation do not need anticoagulation therapy with warfarin? 
Evidence-Based Answer 
Anticoagulation therapy with warfarin is not indicated for use in patients with non-valvular atrial 
fibrillation who are at low risk for embolic cerebral vascular events. The classification of "low 
risk for embolic stroke" is defined as a 1 percent annual risk for stroke or lone atrial fibrillation 
(i.e., age younger than 65 years without history of hypertension, transient ischemic attack, stroke, 
coronary heart disease, recent congestive heart failure, or diabetes). 
Anticoagulation therapy with warfarin is beneficial in patients with atrial fibrillation who are at 
moderate or high risk for stroke. Patients with absolute contraindications to anticoagulation 
therapy (e.g., thrombocytopenia, recent trauma or surgery, hemorrhagic stroke, alcoholism) 
should not take warfarin.
1,2
 [Strength of recommendation: A, based on meta-analyses of large 
randomized controlled trials (RCTs)] 
Evidence Summary 
A number of meta-analyses of RCTs evaluating prevention of stroke in patients with atrial 
fibrillation demonstrated the benefits of warfarin therapy.
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 The Atrial Fibrillation Investigators 
pooled data from five large RCTs covering 3,691 patient-years. The annual rate of stroke was 
found to be 4.5 percent among the control groups and 1.4 percent in the warfarin groups. The 
absolute risk reduction (RR) was 3.1 percent (95 percent confidence interval [CI], 2.3 to 3.6 
percent), and the number needed to treat (NNT) was 32.
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A 1999 meta-analysis of 16 RCTs covering 16,785 patient-years showed that the placebo groups 
had a 6 percent annual stroke rate compared with a 2.2 percent annual stroke rate in the warfarin 
groups. The absolute RR was 3.8 percent (95 percent CI, 2.9 to 4.3 percent), and the NNT was 
26.
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Both meta-analyses reported slightly higher annual rates of major bleeding events among 
patients taking warfarin (1.3 percent) compared with those taking placebo (1 percent) or aspirin 
(1 percent).
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The meta-analyses showed aspirin therapy had a modest stroke risk reduction compared with 
placebo. In the first meta-analysis, the absolute RR was 1.6 percent (95 percent CI, 0.2 to 2.6 
percent), and the NNT was 62.1. In the second meta-analysis, the absolute RR was 1.7 percent 
(95 percent CI, 0.2 to 3.0 percent), and the NNT was 59.
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Risk stratification and subgroup analysis of data from the Atrial Fibrillation Investigators showed 
that warfarin therapy has limited benefit in patients who have atrial fibrillation and no other risk 
factors. Patients younger than 65 years without other risk factors had an annual risk for stroke of 
1 percent whether they were taking warfarin or not. In patients with higher risk for embolic 
cerebral vascular accidents, the relative RR remained constant, and the absolute RR increased 
with the annual stroke rate. Stroke risk was reduced from an untreated rate ranging from 4.3 to 
12 percent annually to a treated rate of 1.1 to 4 percent annually.
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Patients with absolute contraindications to warfarin anticoagulation therapy (e.g., 
thrombocytopenia, recent trauma or surgery, hemorrhagic stroke, alcoholism) should not receive 
warfarin. These patients were systematically excluded from all RCTs of warfarin and atrial 
fibrillation. 
Based on this evidence, warfarin therapy is not indicated for low-risk patients but is beneficial in 
moderate- and high-risk patients. Defining the exact risk for stroke is the critical task in 
determining if a patient should take warfarin (see accompanying table).
4-7
 As the risk for stroke 
increases, the NNT decreases. A relatively small but statistically significant risk for hemorrhage 
with warfarin therapy requires that individual patient characteristics be considered. 
 
 
 
 
 
  
Definitions of Low Risk for Stroke* 
 
Model Definition 
Joint Panel of the American Academy of Family 
Physicians and the American College of Physicians
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History or presence of no more than one of 
the following: 
• CHF within 100 days 
• Hypertension 
• Age > 75 years 
• Diabetes 
American College of Chest Physicians
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 Age < 65 years and all of the following: 
• No hypertension 
• No diabetes 
• No CHD 
• No CHF 
American College of Cardiology, American Heart 
Association, and European Society of Cardiology
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Age < 60 years, CHD but no CHF (LVEF 
> 0.35) and no hypertension 
or 
Age < 75 years, but no CHF, hypertension, 
CHD, or diabetes 
Stroke Prevention in Atrial Fibrillation III Study
7
 Male or female, age < 75 years, and all of 
the following: 
• No hypertension 
• No recent CHF 
• No severe LV dysfunction 
 
 
*-All models consider a history of thromboembolism to be high risk. 
CHF = congestive heart failure; CHD = coronary heart disease; LVEF = left ventricular ejection 
fraction; LV = left ventricle. 
Information from references 4 through 7. 
  
 
 
Recommendations from Others 
The American Academy of Family Physicians, the American College of Physicians,
4
 the 
American College of Chest Physicians,
5
 the American College of Cardiology, the American 
Heart Association, and the European Society of Cardiology
6
 have published recommendations 
consistent with this evidence-based answer. 
Clinical Commentary 
In practice, the decision to anticoagulate with warfarin can be complex. The evidence supports 
quantifying the patient's risk for embolic stroke. However, patients at greatest risk for stroke 
often have a risk for hemorrhage or difficulty complying with warfarin therapy monitoring. In 
some patients, other antiplatelet and antithrombotic agents such as aspirin and clopidogrel 
(Plavix) remain a reasonable alternative. 
RICHARD A. GUTHMANN, M.D. 
University of Illinois at Chicago, Advocate Illinois Masonic Family Practice Residency, 
Chicago, Illinois 
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